Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo

被引：0

作者：

Petrylak, D. ^{[1
]}

Eigl, B. ^{[2
]}

Senkus, E. ^{[3
]}

Loriot, Y. ^{[4
]}

Twardowski, P. ^{[5
]}

Castellano, D. ^{[6
]}

Blais, N. ^{[7
]}

Sridhar, S. ^{[6
,8
]}

Sternberg, C. ^{[9
]}

Retz, M. ^{[10
]}

Blumenstein, B. ^{[11
]}

Jacobs, C. ^{[12
]}

Stewart, P. ^{[13
]}

Bellmunt, J. ^{[14
]}

机构：

[1] Yale Canc Ctr, Prostate & Urol Canc Program, New Haven, CT USA

[2] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada

[3] Uniwersyteckie Ctr Klin, Klin Onkol & Radioterapii, Gdansk, Poland

[4] Gustave Roussy Canc Ctr, Dept Canc Med, Villejuif, France

[5] City Hope Natl Med Ctr, Med Oncol, Duarte, CA 91010 USA

[6] Hosp Univ 12 Octubre, Serv Oncol Med, Madrid, Spain

[7] Univ Montreal, Dept Med, CHUM Hop Notre Dame, Montreal, PQ H3C 3J7, Canada

[8] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[9] San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy

[10] Tech Univ Munich, Urol Klin & Poliklin, D-80290 Munich, Germany

[11] Tri Arc Consulting, Washington, DC USA

[12] OncoGenex Pharmaceut Inc, Clin Res, Bothell, WA USA

[13] OncoGenex Pharmaceut Inc, Clin Dev, Bothell, WA USA

[14] Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1016/S0959-8049(16)31454-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2637

引用

页码：S525 / S525

页数：1